$BIXT
BIOXYTRAN, INC

2023 Q3 Form 10-Q Financial Statement

#000149315223026050 Filed on July 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $669.3K $872.0K $494.1K
YoY Change -236.57% 76.5% 52.65%
% of Gross Profit
Research & Development $316.1K $149.6K $43.14K
YoY Change -33.57% 246.86% -94.0%
% of Gross Profit
Depreciation & Amortization $1.810K $2.190K $1.820K
YoY Change 98.9% 20.33%
% of Gross Profit
Operating Expenses $985.5K $1.022M $537.2K
YoY Change -7027.69% 90.18% -48.46%
Operating Profit -$985.5K -$1.022M -$537.2K
YoY Change -7027.69% 90.18% -48.46%
Interest Expense -$48.70K -$388.1K -$96.82K
YoY Change -77.5% 300.86% -4.44%
% of Operating Profit
Other Income/Expense, Net -$50.50K -$390.3K -$96.82K
YoY Change -76.77% 303.14% -4.45%
Pretax Income -$1.036M -$1.412M -$634.0K
YoY Change 409.95% 122.7% -44.56%
Income Tax
% Of Pretax Income
Net Earnings -$1.001M -$1.411M -$622.3K
YoY Change 709.75% 126.76% -30.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01 -$5.615K
COMMON SHARES
Basic Shares Outstanding 132.5M shares 130.6M shares 110.8M shares
Diluted Shares Outstanding 136.4M shares 128.8M shares 110.8M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.27K $45.18K $500.7K
YoY Change -78.55% -90.98% 29.03%
Cash & Equivalents $80.27K $45.18K $500.7K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $80.27K $45.18K $500.7K
YoY Change -78.55% -90.98% -43.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $108.8K $97.88K $67.55K
YoY Change 46.3% 44.9% 256.27%
TOTAL ASSETS
Total Short-Term Assets $80.27K $45.18K $500.7K
Total Long-Term Assets $108.8K $97.88K $67.55K
Total Assets $189.0K $143.1K $568.2K
YoY Change -57.85% -74.82% -37.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $377.6K $200.5K $1.062M
YoY Change 10.56% -81.12%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.900M $2.000M $3.594M
YoY Change -11.94% -44.35% 74.26%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.333M $2.769M $5.329M
YoY Change -22.17% -48.03% 140.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.333M $2.769M $5.329M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.333M $2.769M $5.329M
YoY Change -22.17% -48.03% 61.45%
SHAREHOLDERS EQUITY
Retained Earnings -$14.45M -$13.41M -$10.29M
YoY Change 38.79% 30.38% 42.1%
Common Stock $144.4K $132.0K $110.8K
YoY Change 17.35% 19.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.485M -$2.002M -$4.761M
YoY Change
Total Liabilities & Shareholders Equity $189.0K $143.1K $568.2K
YoY Change -57.85% -74.82% -37.3%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$1.001M -$1.411M -$622.3K
YoY Change 709.75% 126.76% -30.6%
Depreciation, Depletion And Amortization $1.810K $2.190K $1.820K
YoY Change 98.9% 20.33%
Cash From Operating Activities -$342.6K -$153.3K -$238.8K
YoY Change -52.34% -35.81% -76.56%
INVESTING ACTIVITIES
Capital Expenditures $12.69K $20.34K -$120.00
YoY Change -264.59% -17050.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$12.69K -$20.34K -$120.00
YoY Change 64.59% 16850.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 390.4K 65.00K 0.000
YoY Change -34.94% -100.0%
NET CHANGE
Cash From Operating Activities -342.6K -153.3K -238.8K
Cash From Investing Activities -12.69K -20.34K -120.0
Cash From Financing Activities 390.4K 65.00K 0.000
Net Change In Cash 35.09K -108.6K -238.9K
YoY Change -127.74% -54.54% -180.6%
FREE CASH FLOW
Cash From Operating Activities -$342.6K -$153.3K -$238.8K
Capital Expenditures $12.69K $20.34K -$120.00
Free Cash Flow -$355.3K -$173.6K -$238.7K
YoY Change -50.04% -27.26% -76.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001445815
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Paid In Kind Interest
PaidInKindInterest
usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
BIXT Debt Discount On Convertible Note
DebtDiscountOnConvertibleNote
usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
BIXT Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
shares
BIXT Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
BIXT Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
shares
BIXT Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35027
dei Entity Registrant Name
EntityRegistrantName
BIOXYTRAN, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2797630
dei Entity Address Address Line1
EntityAddressAddressLine1
75 2nd Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 605
dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
454-1199
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
132535294 shares
CY2023Q2 us-gaap Cash
Cash
45181 usd
CY2022Q4 us-gaap Cash
Cash
295401 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
45181 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
295401 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
97880 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
75535 usd
CY2023Q2 us-gaap Assets
Assets
143061 usd
CY2022Q4 us-gaap Assets
Assets
370936 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
562662 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
749395 usd
CY2023Q2 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
380 usd
CY2022Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
960 usd
CY2023Q2 BIXT Unissued Shares Liability Related Party Current
UnissuedSharesLiabilityRelatedPartyCurrent
5700 usd
CY2022Q4 BIXT Unissued Shares Liability Related Party Current
UnissuedSharesLiabilityRelatedPartyCurrent
38400 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2165000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2769242 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3663482 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2769242 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3663482 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132035294 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132035294 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123252235 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123252235 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
132035 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
123252 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11279970 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8392430 usd
CY2023Q2 us-gaap Minority Interest
MinorityInterest
-624286 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-590628 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13413901 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11217600 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2626182 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3292546 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143060 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
370936 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
149638 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43141 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
288642 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
283266 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
866932 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
447360 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1464570 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1003941 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5110 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
46723 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18710 usd
us-gaap Share Based Compensation
ShareBasedCompensation
69123 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1021680 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
537224 usd
us-gaap Operating Expenses
OperatingExpenses
1771922 usd
us-gaap Operating Expenses
OperatingExpenses
1356330 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1021680 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-537224 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1771922 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1356330 usd
CY2023Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
39477 usd
CY2022Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
54480 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
106698 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
106515 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2188 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
911 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2702 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1822 usd
CY2023Q2 BIXT Debt Discount Amortization And Issuance Of Warrants
DebtDiscountAmortizationAndIssuanceOfWarrants
348637 usd
CY2022Q2 BIXT Debt Discount Amortization And Issuance Of Warrants
DebtDiscountAmortizationAndIssuanceOfWarrants
41425 usd
BIXT Debt Discount Amortization And Issuance Of Warrants
DebtDiscountAmortizationAndIssuanceOfWarrants
348637 usd
BIXT Debt Discount Amortization And Issuance Of Warrants
DebtDiscountAmortizationAndIssuanceOfWarrants
132759 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-390302 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-96816 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-458037 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-241096 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1411982 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-634040 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2229959 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1597426 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1411982 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-634040 usd
us-gaap Profit Loss
ProfitLoss
-2229959 usd
us-gaap Profit Loss
ProfitLoss
-1597426 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-764 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11691 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-33658 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-62807 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1411218 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-622349 usd
us-gaap Net Income Loss
NetIncomeLoss
-2196301 usd
us-gaap Net Income Loss
NetIncomeLoss
-1534619 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128804789 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128804789 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128804789 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110840998 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110840998 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110840998 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126224323 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126224323 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126224323 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110840998 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110840998 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110840998 shares
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3158207 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
42250 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-51116 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-912270 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4079343 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11691 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-622349 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4713383 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3292546 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
80000 usd
CY2023Q1 BIXT Additional Paid In Capital In Stock Subscription
AdditionalPaidInCapitalInStockSubscription
30000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-32894 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-785083 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4060523 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
65000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50200 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1790 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2164340 usd
CY2023Q2 BIXT Stock Issued During Period Value Shares Issued To Consultants For Conversion Of Debt
StockIssuedDuringPeriodValueSharesIssuedToConsultantsForConversionOfDebt
44050 usd
CY2023Q2 BIXT Stock Issued During Period Value For Conversion Of Debt
StockIssuedDuringPeriodValueForConversionOfDebt
172306 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
348637 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-764 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1411218 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2626182 usd
us-gaap Profit Loss
ProfitLoss
-2229959 usd
us-gaap Profit Loss
ProfitLoss
-1597426 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
348637 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
132759 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2702 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1822 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18710 usd
us-gaap Share Based Compensation
ShareBasedCompensation
69123 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
7306 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-142682 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-67481 usd
BIXT Increase Decrease Accounts Payable Related Party
IncreaseDecreaseAccountsPayableRelatedParty
1655113 usd
BIXT Increase Decrease Accounts Payable Related Party
IncreaseDecreaseAccountsPayableRelatedParty
531000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-340173 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-930203 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25047 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
22438 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25047 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22438 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
115000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1380960 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
115000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1380960 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-250220 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
428319 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
295401 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72358 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45181 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
500677 usd
us-gaap Interest Paid Net
InterestPaidNet
52425 usd
us-gaap Interest Paid Net
InterestPaidNet
69900 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
348637 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
42250 usd
BIXT Debt Discount On Convertible Note
DebtDiscountOnConvertibleNote
90509 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
172306 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_z4JwXfBkQO0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zELAEZJG5Z7a">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
288642 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
283266 usd
CY2023Q2 us-gaap Cash
Cash
45181 usd
CY2023Q2 BIXT Working Capital
WorkingCapital
-2724061 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13413901 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
115000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1380960 usd
BIXT Reimbursement Of Legal And Administrative Costs
ReimbursementOfLegalAndAdministrativeCosts
25720 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P20Y
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
104226 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
79179 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6346 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-3644 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
97880 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
75535 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
200500 usd
CY2023Q2 BIXT Unissued Shares Liability Related Party Current
UnissuedSharesLiabilityRelatedPartyCurrent
5700 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
709727 usd
CY2022Q4 BIXT Unissued Shares Liability Related Party Current
UnissuedSharesLiabilityRelatedPartyCurrent
38400 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
200500 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
709727 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
315502 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
393085 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
181548 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
134581 usd
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
15941 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
40182 usd
CY2023Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
48125 usd
CY2022Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
180557 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1546 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
990 usd
CY2023Q2 BIXT Unissued Shares Liability Related Party Current
UnissuedSharesLiabilityRelatedPartyCurrent
5700 usd
CY2022Q4 BIXT Unissued Shares Liability Related Party Current
UnissuedSharesLiabilityRelatedPartyCurrent
38400 usd
CY2023Q2 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
380 usd
CY2022Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
960 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2165000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2769242 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3663482 usd
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2000000 usd
CY2023Q2 BIXT Debt Instrument Interest Payable
DebtInstrumentInterestPayable
181548 usd
CY2022Q4 BIXT Debt Instrument Interest Payable
DebtInstrumentInterestPayable
134581 usd
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
2181548 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
2299581 usd
CY2023Q2 BIXT Debt Instrument Redemption Amount
DebtInstrumentRedemptionAmount
2000000 usd
CY2023Q2 BIXT Debt Instrument Reissue For Settlement Amount
DebtInstrumentReissueForSettlementAmount
1000000 usd
CY2022Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
6081484 shares
CY2022Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1467000 usd
CY2022Q3 BIXT Debt Conversion Converted Instrument Accrued Interest Converted
DebtConversionConvertedInstrumentAccruedInterestConverted
53371 usd
CY2022Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
6081484 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123252235 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123252235 shares
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
93750 shares
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000 usd
CY2023Q1 us-gaap Share Price
SharePrice
0.32
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
156250 shares
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
CY2023Q1 us-gaap Share Price
SharePrice
0.32
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
78125 shares
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 usd
CY2023Q2 us-gaap Share Price
SharePrice
0.32
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
114286 shares
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40000 usd
CY2023Q2 us-gaap Share Price
SharePrice
0.32
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132035294 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132035294 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123252235 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123252235 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
272000 shares
CY2021Q4 BIXT Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
2.00
BIXT Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2
P2Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
264030 shares
BIXT Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
0.26
BIXT Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Granted Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm2
P5Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
536030 shares
CY2022Q2 BIXT Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
1.14
BIXT Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 End
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2End
P3Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
542030 shares
CY2022Q4 BIXT Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.42
BIXT Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
800000 shares
BIXT Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
0.20
BIXT Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Granted Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm2
P5Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1342030 shares
CY2023Q2 BIXT Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.29
BIXT Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 End
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2End
P4Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
264030 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
800000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.20
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.001
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
0.95
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
428000 shares
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.52
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P0Y7M28D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11175 usd
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
428000 shares
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
0.52
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P0Y7M28D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11175 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P0Y7M28D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11175 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd

Files In Submission

Name View Source Status
0001493152-23-026050-index-headers.html Edgar Link pending
0001493152-23-026050-index.html Edgar Link pending
0001493152-23-026050.txt Edgar Link pending
0001493152-23-026050-xbrl.zip Edgar Link pending
bixt-20230630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bixt-20230630_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
bixt-20230630_lab.xml Edgar Link unprocessable
bixt-20230630_cal.xml Edgar Link unprocessable
bixt-20230630_pre.xml Edgar Link unprocessable